165 related articles for article (PubMed ID: 15623645)
1. Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer.
Onn A; Isobe T; Wu W; Itasaka S; Shintani T; Shibuya K; Kenji Y; O'reilly MS; Fidler IJ; Herbst RS
Clin Cancer Res; 2004 Dec; 10(24):8613-9. PubMed ID: 15623645
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor blockade potentiates apoptosis mediated by Paclitaxel and leads to prolonged survival in a murine model of oral cancer.
Holsinger FC; Doan DD; Jasser SA; Swan EA; Greenberg JS; Schiff BA; Bekele BN; Younes MN; Bucana CD; Fidler IJ; Myers JN
Clin Cancer Res; 2003 Aug; 9(8):3183-9. PubMed ID: 12912971
[TBL] [Abstract][Full Text] [Related]
3. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice.
Kim SJ; Uehara H; Karashima T; Shepherd DL; Killion JJ; Fidler IJ
Clin Cancer Res; 2003 Mar; 9(3):1200-10. PubMed ID: 12631626
[TBL] [Abstract][Full Text] [Related]
4. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer.
Younes MN; Yazici YD; Kim S; Jasser SA; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3425-34. PubMed ID: 16740767
[TBL] [Abstract][Full Text] [Related]
5. Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice.
Onn A; Isobe T; Itasaka S; Wu W; O'Reilly MS; Ki Hong W; Fidler IJ; Herbst RS
Clin Cancer Res; 2003 Nov; 9(15):5532-9. PubMed ID: 14654533
[TBL] [Abstract][Full Text] [Related]
6. Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade.
Yigitbasi OG; Younes MN; Doan D; Jasser SA; Schiff BA; Bucana CD; Bekele BN; Fidler IJ; Myers JN
Cancer Res; 2004 Nov; 64(21):7977-84. PubMed ID: 15520205
[TBL] [Abstract][Full Text] [Related]
7. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
[TBL] [Abstract][Full Text] [Related]
8. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice.
Weber KL; Doucet M; Price JE; Baker C; Kim SJ; Fidler IJ
Cancer Res; 2003 Jun; 63(11):2940-7. PubMed ID: 12782601
[TBL] [Abstract][Full Text] [Related]
9. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice.
Kim SJ; Uehara H; Yazici S; Langley RR; He J; Tsan R; Fan D; Killion JJ; Fidler IJ
Cancer Res; 2004 Jun; 64(12):4201-8. PubMed ID: 15205332
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice.
Yazici S; Kim SJ; Busby JE; He J; Thaker P; Yokoi K; Fan D; Fidler IJ
Prostate; 2005 Nov; 65(3):203-15. PubMed ID: 15948138
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer.
Volante M; Saviozzi S; Rapa I; Ceppi P; Cappia S; Calogero R; Novello S; Borasio P; Papotti M; Scagliotti GV
Cancer; 2007 Sep; 110(6):1321-8. PubMed ID: 17647268
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation.
Luppi F; Longo AM; de Boer WI; Rabe KF; Hiemstra PS
Lung Cancer; 2007 Apr; 56(1):25-33. PubMed ID: 17175059
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
Zhang L; Lau YK; Xia W; Hortobagyi GN; Hung MC
Clin Cancer Res; 1999 Feb; 5(2):343-53. PubMed ID: 10037184
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M
Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856
[TBL] [Abstract][Full Text] [Related]
16. Mitogen-activated protein kinase phosphatase-1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor-tyrosine kinase.
Takeuchi K; Shin-ya T; Nishio K; Ito F
FEBS J; 2009 Mar; 276(5):1255-65. PubMed ID: 19175673
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells.
Lei W; Mayotte JE; Levitt ML
Anticancer Res; 1999; 19(1A):221-8. PubMed ID: 10226546
[TBL] [Abstract][Full Text] [Related]
18. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
Johnson FM; Saigal B; Donato NJ
J Cell Physiol; 2005 Nov; 205(2):218-27. PubMed ID: 15887238
[TBL] [Abstract][Full Text] [Related]
19. Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation.
Younes MN; Yigitbasi OG; Park YW; Kim SJ; Jasser SA; Hawthorne VS; Yazici YD; Mandal M; Bekele BN; Bucana CD; Fidler IJ; Myers JN
Cancer Res; 2005 Jun; 65(11):4716-27. PubMed ID: 15930290
[TBL] [Abstract][Full Text] [Related]
20. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
